Product Description
| Cat Number | SB039 |
|---|---|
| Category | Peptide |
| Pack Size | 1 Kit |
| Description | KLPGF peptide is a sequence from egg white albumen. This peptide have recently shown interest for Alzheimer’s disease. Involvement in Alzheimer’s disease This peptide fragment, KLPGF, demonstrated recently an activity against Acetylcholinesterase (AchE), which is implicated in Alzheimer’s diseases and corresponds to the target of almost all Alzheimer’s disease treatmets. Actually, a deficiency in the brain levels of acetylcholine is seen as key step in the pathogenesis of Alzheimer disease. Otherwise, KLPGF peptide seems to inhibit the activity of Butyrylcholinesterase (BchE) and Beta-site APP cleaving enzyme 1 (BACE1), which is one of the most promising new therapeutic approaches for Alzheimer’s diseases. Indeed, this receptor induce the formation of Amyloid Beta, a typical peptide from Alzheimer’s diseases. In a recent study (Zhipeng Yu et al, Biological evaluation and interaction mechanism of beta-site APP cleaving enzyme 1 inhibitory pentapeptide from egg albumin, Food Science and Human Wellness, 2020), molecular docking and Dynamics simulations of peptide KLPGF and BACE1 were performed. It seems that Lys321, Asp228, and Asn233 play important roles in the BACE1 inhibitory peptide design. Antidiabetic activity KLPGF peptide also shown an antidiabetic activity by inhibiting α-glucosidase and α-amylase. |
| Disulfide Bonds | _ |
| Note | The product is for research use only |
Share Item: